WebNews

Please enter a web search for web results.

NewsWeb

USA Today
usatoday. com > press-release > story > 33500 > heliaus-gov-wins-2026-govies-award-for-ai-powered-security-workforce-management-platform

HELIAUS Gov Wins 2026 GOVIES Award for AI-Powered Security Workforce Management Platform

7+ hour, 6+ min ago  (294+ words) IRVINE, CA / ACCESS Newswire / May 27, 2026 / Allied Universal, the world's leading security and facility services. .. HELIAUS Gov Wins 2026 GOVIES Award for AI-Powered Security Workforce Management Platform IRVINE, CA / ACCESS Newswire / May 27, 2026 / Allied Universal, "the world's leading security and facility services company,…...

Symbols: nasdaq:tenb
pharmabiz. com
pharmabiz. com > News Details. aspx

Biocytogen introduces AI-powered Ren Super platform and industry-first fully automated antibody discovery infrastructure

15+ hour, 45+ min ago  (111+ words) Beijing, China Wednesday, May 27, 2026, 18: 00 Hrs [IST] Bi. .. Biocytogen introduces AI-powered Ren Super platform and industry-first fully automated antibody discovery infrastructure Biocytogen, a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, announced the…...

Symbols: btc-usd
markets. businessinsider. com
markets. businessinsider. com > news > stocks > traws-pharma-announces-antiviral-program-targeting-ongoing-hantavirus-and-ebola-virus-disease-outbreaks-1036197994

Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks

2+ hour, 30+ min ago  (160+ words) Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a low pill burden option to manage existing and future outbreaks Interactions planned with the US Centers for Disease Control and Prevention (CDC), and ongoing with the…...

Symbols: nasdaq:traw,asx:ila
markets. businessinsider. com
markets. businessinsider. com > news > stocks > seer-to-showcase-ai-driven-multi-cancer-screening-approach-and-next-generation-proteomics-capabilities-at-asms-2026-1036195409

Seer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026

19+ hour, 10+ min ago  (81+ words) Seer Breakfast Symposium ID-free AI Proteomics for Multi-Cancer Screening Date: Monday, June 1, 2026 | Time: 7: 00 a. m. PT | Location: Conference Center, Room 33 B Seer Oral Presentation Building Scalable Proteomics with Radiant DIA" and the Fulcrum Pipeline" Date: Tuesday, June 2, 2026 | Time: 9: 50 a. m. PT | Location: Ballroom 20 BC…...

Symbols: nasdaq:exas,btc-usd
PYMNTS. com
pymnts. com > news > investment-tracker > 2026 > cognition-raises-1-billion-to-expand-ai-powered-software-engineer

Cognition Raises $1 Billion to Expand AI-Powered Software Engineer

2+ hour ago  (465+ words) Artificial intelligence (AI) startup Cognition said it is now a $26 billion company. As the company said in its announcement Wednesday (May 27), Cognition reached that valuation after raising more than $1 billion in a new Series D funding round, financing it will…...

Symbols: nasdaq:meta
markets. businessinsider. com
markets. businessinsider. com > news > stocks > immix-biopharma-announces-95-complete-response-rate-in-interim-update-from-relapsed-refractory-al-amyloidosis-clinical-trial-nexicart-2-1036182840

Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2

6+ day, 5+ hour ago  (197+ words) " "Of first 20 patients, all four MRD-negative patients have converted to complete response (CR)" " " "CR rate now 95% (19 of 20 patients)" " " All CRs reached within 1 year of follow-up post-dosing" " " No relapses to-date observed for patients who have reached CR" " " All subsequently enrolled patients…...

Symbols: nyse:anvs,attr-cm,nasdaq:mnov
Forbes
forbes. com > councils > forbesbusinessdevelopmentcouncil > 05/27/2026 > lessons-from-pivoting-industries-after-decades-in-one-sector

Lessons From Pivoting Industries After Decades In One Sector

10+ hour, 15+ min ago  (194+ words) Tracy Nolan is a Fortune 100 executive, board director and change advisor known for transforming moments of change into growth catalysts. I've learned that purpose is what carries you through the transition period. When you're learning a new industry and building…...

Symbols: nyse:xom,nyse:cvx,nyse:fcx,nyse:cat,nyse:de,nasdaq:aapl
Yahoo Finance
finance. yahoo. com > sectors > technology > articles > navee-takes-home-five-gold-100400687. html

NAVEE Takes Home Five Gold and One Silver at the 2026 NY Product Design Awards

1+ day, 7+ hour ago  (320+ words) The NY Product Design Gold Awards went to the NAVEE UT5, NT5 and ST5 electric scooter series, along with the Eagle F1 and Eagle L1 E-golf push cart series. The NAVEE XT5 series received a Silver Award, underscoring NAVEE's growing influence across both urban mobility ecosystem…...

Symbols: btc-usd
Yahoo Finance
finance. yahoo. com > sectors > healthcare > articles > asahi-kasei-life-science-acquires-123000815. html

Asahi Kasei Life Science Acquires License for Novel Antibody-Drug Conjugate Technology from The Noguchi Institute " A Major Milestone for More Efficient and Safer Cancer Treatments

4+ hour, 45+ min ago  (317+ words) TOKYO, May 27, 2026--Asahi Kasei Life Science has acquired the license rights for a novel antibody-drug conjugate (ADC) technology from The Noguchi Institute. .. Oops, something went wrong Asahi Kasei Life Science Acquires License for Novel Antibody-Drug Conjugate Technology from The Noguchi…...

Symbols: btc-usd,eth-usd,nasdaq:vivs
markets. businessinsider. com
markets. businessinsider. com > news > stocks > molecular-partners-publishes-phase-1-mp0317-data-in-nature-cancer-demonstrating-tumor-localized-cd40-activation-and-tumor-microenvironment-remodeling-1036094079

Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling

3+ week, 5+ day ago  (648+ words) ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. , May 01, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech. .. Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling…...

Symbols: nasdaq:iova,nasdaq:cccc,nasdaq:imcr